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ARTICLE
Molecular Diagnostics
Prognostic role of carcinoembryonic antigen and carbohydrate
antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant
subset with high CA 19-9 level and poor outcome
Maria Thomsen1,2, Eva Skovlund3, Halfdan Sorbye4, Nils Bolstad5, Kjell Johannes Nustad5, Bengt Glimelius6, Per Pfeiffer7,8, Elin H. Kure9,
Julia S. Johansen10, Kjell Magne Tveit1,2,11, Thoralf Christoffersen12 and Tormod Kyrre Guren1,11
BACKGROUND: Mutation status of RAS and BRAF, as well as serum levels of carcinoembryonic antigen (CEA) and carbohydrate
antigen 19-9 (CA 19-9), are biomarkers used in clinical management of patients with gastrointestinal cancers. This study aimed to
examine the prognostic role of these biomarkers in a patient population that started ﬁrst-line chemotherapy for unresectable
metastatic colorectal cancer (mCRC) in the NORDIC-VII study.
METHODS: CEA and CA 19-9 were measured in serum samples from 545 patients obtained before the start of chemotherapy. Four
hundred and ninety-four patients had detectable levels of carbohydrate antigen 19-9 (CA 19-9). RAS (exons 2–4) and BRAF (V600E)
mutation status were available from 440 patients. Overall survival (OS) was estimated in patient groups deﬁned by serum CEA or CA
19-9 levels using cut-off values of 5 µg/L and 35 kU/L, respectively, in the total population and in subgroups according to RAS and
BRAF mutation status.
RESULTS: For both CEA and CA 19-9, elevated serum levels were associated with reduced OS in adjusted analyses which included
RAS and BRAF mutation status, baseline World Health Organization performance status, and levels of alkaline phosphatase and C-
reactive protein. The negative prognostic information provided by an elevated CA 19-9 level was particularly marked in patients
with BRAF mutation (hazard ratio= 4.35, interaction P= 0.003, in an adjusted model for OS).
CONCLUSIONS: High baseline serum concentrations of CEA and CA 19-9 provide independent information of impaired prognosis
in mCRC. In patients with BRAF-mutant tumours, elevated serum CA 19-9 may identify a subgroup with highly aggressive disease
and could contribute to improving therapeutic decisions.
British Journal of Cancer https://doi.org/10.1038/s41416-018-0115-9
INTRODUCTION
Colorectal cancer (CRC) is the third most common cancer and
40–50% of patients with CRC will develop distant metastases.1
Systemic therapy is the main treatment option for metastatic CRC
(mCRC), and better treatment during the past decades has
resulted in improved survival. However, mCRC is a heterogeneous
disease, and selecting patients for optimal treatment is a
challenge. Many factors determine the outcome. Development
of robust and easily available biomarkers may help to individualise
treatment.
Mutations in RAS (exons 2–4) and particularly BRAF (V600E) in
the tumour cells are associated with impaired prognosis,2–6 and
mutation status is routinely used in the clinical management of
patients with mCRC. About 50% of the patients have RAS
mutations which predict lack of effect from systemic treatment
with epidermal growth factor receptor (EGFR) antibodies.7,8 The
activating BRAF (V600E) mutation is found in 5–20% of the
tumours in mCRC patient cohorts.3,5,6,9
Assays of certain glycoproteins and carbohydrates expressed by
cancer cells are used in the clinical management of patients with
gastrointestinal malignancies.10,11 Carcinoembryonic antigen
(CEA), a glycoprotein belonging to a group of adhesion molecules,
is produced in the epithelium of the large intestine and may be
involved in malignancy.12 CEA has an established role as a
biomarker in diagnosis, treatment and surveillance in CRC,10 and
elevated serum levels of CEA are associated with inferior
prognosis.10,13,14 Carbohydrate antigen 19-9 (CA 19-9), a tetra-
saccharide carbohydrate also termed sialyl Lewis a, synthesised by
gastrointestinal epithelium, is an established serum biomarker for
monitoring treatment of patients with pancreatic cancer. While
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there is some evidence of a relationship between elevated CA 19-
9 levels and outcome in CRC,15–17 its role in the management of
patients with mCRC is so far unclear.10,18 Little is also known about
the prognostic information that can be obtained from the serum
levels of these two biomarkers when analysed in relation to
tumour RAS and BRAF mutation status.
One particular focus of the present study is the group of
patients with BRAF-mutant tumours. Although the presence of
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Table 1. Baseline patient characteristics
Variables Study populations
Total (n=
566)
CEA/CA 19-9
analysed (n= 545)
CA 19-9 detected
(n= 494)
CA 19-9 not
detected (n= 51)
CEA analysed RAS/BRAF
analysed (n= 440)
CA 19-9 detected RAS/
BRAF analysed (n= 399)
Age (years)
Median (min, max) 62 (24, 75) 62 (24, 75) 62 (24, 75) 60 (30, 75) 62 (24, 75) 62 (24, 75)
Gender, n (%)
Male 334 (59) 322 (59) 292 (59) 30 (59) 265 (60) 241 (60)
Female 232 (41) 223 (41) 202 (41) 21 (41) 175 (40) 158 (40)
WHO performance status, n (%)
0 380 (67) 367 (67) 328 (66) 39 (76) 295 (67) 263 (67)
1 162 (29) 155 (28) 145 (29) 10 (20) 126 (29) 119 (29)
2 24 (4) 23 (4) 21 (4) 2 (4) 19 (4) 17 (4)
Location primary tumour, n (%)
Colon 333 (59) 321 (59) 297 (60) 24 (47) 265 (60) 244 (61)
Rectum 233 (41) 224 (41) 197 (40) 27 (53) 175 (40) 155 (39)
Previous surgery, n (%)
Primary tumour
resected
382 (67) 369 (68) 334 (68) 35 (69) 335 (76) 303 (76)
Intact primary
tumour
184 (33) 176 (32) 160 (32) 16 (31) 105 (24) 96 (24)
Prior pelvic RT, n (%)
Yes 80 (14) 75 (14) 68 (14) 7 (14) 66 (15) 60 (15)
No 486 (86) 470 (86) 426 (86) 44 (86) 374 (85) 339 (85)
Prior adjuvant CT, n (%)
Yes 51 (9) 49 (9) 42 (9) 7 (14) 44 (10) 38 (10)
No 515 (91) 496 (91) 452 (91) 44 (86) 396 (90) 351 (90)
Time of metastases, n (%)
Synchronous 402 (71) 389 (71) 347 (70) 42 (82) 298 (68) 266 (67)
Metachronous 164 (29) 156 (29) 147 (30) 9 (18) 142 (32) 133 (33)
Number of metastatic sites, n (%)
1 site 162 (29) 155 (28) 137 (28) 18 (35) 130 (30) 115 (29)
>1 sites 404 (71) 390 (72) 357 (72) 33 (65) 310 (70) 284 (71)
Alkaline phophatase level, n (%)
Normal 298 (53) 286 (52) 258 (48) 26 (55) 240 (55) 217 (54)
>UNL 268 (47) 259 (48) 236 (48) 23 (45) 200 (45) 182 (46)
Platelet count, n (%)
≤400/nL 398 (70) 383 (70) 347 (70) 36 (71) 315 (72) 287 (72)
>400/nL 168 (30) 162 (30) 147 (30) 15 (29) 125 (28) 112 (28)
White blood cell count, n (%)
≤10/nL 428 (76) 416 (76) 369 (75) 44 (86) 345 (78) 309 (77)
>10/nL 138 (24) 132 (24) 125 (25) 7 (14) 95 (22) 90 (23)
RAS/BRAF mutation status, n (%)
RAS/BRAF wild-type 15a (37) 186 (42) 171 (43)
RAS mutation 22a (54) 201 (46) 179 (45)
BRAF mutation 4a (10) 53 (12) 49 (12)
CRP level, n (%)
≤10mg/L 18b (45) 194d (45) 176f (45)
>10mg/L 22b (55) 234d (55) 212f (55)
IL-6 level, n (%)
<5.6 ng/L 21c (54) 193e (49) 172g (49)
≥5.6 ng/L 18c (46) 199e (51) 181g (51)
CRP C-reactive protein, CEA carcinoembryonic antigen, CA carbohydrate antigen, CT chemotherapy, IL-6 interleukin-6, PS performance status, RT radiation
therapy, UNL upper normal limit, WHO World Health Organization aAnalysed for RAS/BRAF mutations (n= 41). bCRP (n= 40). cIL-6 (n= 39). dCRP (n= 428). eIL-6
(n= 392). fCRP (n= 388). gIL-6 (n= 353).
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BRAF mutation in general is known to be associated with an
inferior outcome of mCRC,2,4,6 there is a signiﬁcant heterogeneity
within the BRAF-mutant population.9,19,20 It is important to learn
more about the basis for this heterogeneity, since it is conceivable
that optimal therapeutic care might differ for these patients.20,21
We have previously shown that in mCRC patients with BRAF
mutations, evidence of a systemic inﬂammation predicted an
extremely aggressive disease with very short survival.22 Further-
more, during treatment of mCRC patients, we have accidentally
observed high serum levels of CA 19-9 in several patients with
BRAF-mutant tumours. The aim of the present study was to
explore the prognostic information of serum CEA and CA 19-9 in
patients with mCRC, especially as related to RAS and BRAF
mutation status, and with emphasis on CA 19-9 in patients with
BRAF-mutant tumours.
MATERIALS AND METHODS
Patients
The randomised NORDIC-VII study investigated the effects of
combining cetuximab with the Nordic FLOX regimen with bolus 5-
ﬂououracil/folinic acid and oxaliplatin23 in previously untreated
patients with unresectable mCRC.24 A total of 566 patients were
randomly assigned to receive FLOX, cetuximab plus FLOX or
cetuximab combined with intermittent FLOX as ﬁrst-line palliative
chemotherapy. There were no statistically signiﬁcant differences in
outcome (progression-free survival (PFS), overall survival (OS),
overall response rate or secondary R0 resection of metastases)
between the different treatment arms in the NORDIC-VII study.6,24
In the present study, data were analysed across the three
treatment arms.
The CONSORT diagram in Fig. 1 describes the different
patient populations. CA 19-9 and CEA were analysed in serum
from 545 patients. Tumour RAS/BRAF mutation status was
known in 440 of these patients, and further information about
plasma C-reactive protein (CRP) and interleukin-6 (IL-6) level
was available in 428 and 392 patients, respectively. The
different prognostic clinicopathological markers were deﬁned
as alkaline phosphatase (ALP) level normal or elevated (above
upper normal limit (UNL) based on institutional reference
values at the study sites), CRP (below or above 10 mg/L),
platelet count (below or above 400/nL) and white blood cell
count (below or above 10/nL). These cut-off values have been
used in large mCRC phase III trials and in prognostic
indexes.3,8,25,26 The baseline demographics and clinical char-
acteristics of the patients are shown in Table 1.
Mutation analyses of KRAS, NRAS and BRAF
Genomic DNA was extracted from formalin-ﬁxed parafﬁn-
embedded 10 µm tumour tissue sections (65–70% (median)
tumour cells) using QIAamp DNA Micro Kit (Cat. 56304, Qiagen).
Tumour DNA was screened for the presence of RAS (exons 2–4)
and BRAF (V600E) mutations as previously described.6,24
Measurement of CEA and CA 19-9
Fresh-frozen serum samples were obtained from patients before
the start of treatment and after 8 weeks of treatment. The samples
were thawed and mixed before analysis of CEA (Ref. No. 04491777
190) and CA 19-9 (Ref. No. 11776193 122) on the Cobas e601
instrument (Roche Diagnostics GmbH, Mannheim, Germany).
Established Norwegian reference values were used, with cut-off
values 5 µg/L for CEA and 35 kU/L for CA 19-9. Patients with
undetectable levels of CA 19-9 (i.e., below the lower analytical
detection limit; 5 kU/L) were classiﬁed as a separate category in
the primary statistical analyses. The results are presented in
accordance with the REMARK guidelines.27
Statistical analyses
The statistical analyses were performed using IBM SPSS (version
23, IBM Corp., Armonk, NY, USA). Demographic data were
described with median and range (continuous variables) or with
proportions and percentages (categorical variables). The prog-
nostic values of different serum levels of CEA and CA 19-9 and
survival were assessed by Kaplan–Meier method, log-rank test and
Cox proportional hazards model. Separate analyses of the effect of
World Health Organization (WHO) performance status, ALP level,
number of metastatic sites, CRP level and tumour RAS/BRAF
mutation status were performed. Only variables statistically
signiﬁcant (P < 0.05) in these analyses were included in the
multivariable analyses, and models were restricted to include
statistically signiﬁcant variables only. An interaction term was
included in the Cox model to explore the effect of mutation status
on the prognostic effect of serum levels of CEA and CA 19-9.
RESULTS
Clinical characteristics and serum levels of CEA and CA 19-9
The frequency distribution of the levels of CEA and CA 19-9 is
shown in Fig. 2a, b, respectively. From 545 analysed patients, 96
(18%) had serum levels of CEA below 5 µg/L and 449 (82%) had
elevated CEA levels (≥5 µg/L). Furthermore, 494 patients had
detectable serum levels of CA 19-9 in their serum samples. Of
these patients, 188 (38%) had a serum level of CA 19-9 below 35
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Fig. 2 Histograms. Distribution of serum level of (a) CEA (median: 36 µg/L; range: 0.5–32,916 µg/L) and (b) CA 19-9 (median 50 kU/L; range
5–185,991 kU/L). Fifty-one patients had undetectable levels of CA 19-9 in the serum
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kU/L and 306 (62%) had elevated CA 19-9 (≥35 kU/L). From 51
patients (9%), CA 19-9 was below the detection limit.
For both CEA and CA 19-9, elevated serum levels were
associated with impaired baseline clinical patient characteristics,
such as inferior WHO performance status, intact primary tumour,
synchronous metastases, elevated ALP level, elevated platelet
(>400/nL) and white blood cell (>10/nL) counts and elevated CRP
(>10mg/L) (Supplementary Table 1). Elevated CA 19-9 was
somewhat more frequent in patients with colon cancer as
compared to rectal cancer, while there was no association
between CEA level and origin of primary tumour. Furthermore,
33% and 71% of the patients with lung-only metastases had levels
of CEA below 5 µg/L and CA 19-9 below 35 kU/L, respectively. No
relationship between other metastatic sites and serum levels of
CEA or CA 19-9 was observed.
In patients with elevated serum CA 19-9 (≥35 kU/L), the median
was numerically higher in those with with BRAF-mutant tumours
(853 kU/L) compared to those with RAS-mutant or RAS/BRAF wild-
type tumours (336 and 254 kU/L, respectively). Furthermore, 8 of the
16 patients with an isolated elevated CA 19-9 (i.e., CEA not increased)
had BRAF-mutant tumours.There was no difference in median CEA
value between subgroups based on RAS or BRAF mutation status.
Serum level of CEA as an independent prognostic biomarker
As expected, there was a relationship between increasing serum
levels of CEA (grouped in quartiles) and impaired survival (log-rank
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test for trend, P < 0.001). Patients with elevated CEA (≥5 µg/L) and
low CEA (<5 µg/L) had a median OS of 19 and 29 months,
respectively (hazard ratio (HR), 1.85 (95% conﬁdence interval (CI)
1.45–2.38); P < 0.001). Furthermore, 24% of the patients with
serum CEA below 5 µg/L survived at least 5 years compared to 8%
of those with an elevated CEA level (Fig. 3a), although there was
no difference in frequency of secondary metastasectomy in the
two subgroups (9% and 8%, respectively). The prognostic
information of baseline CEA was further conﬁrmed in an adjusted
model including other prognostic markers and clinical character-
istics believed to be potential confounders, including WHO
performance status, ALP and CRP levels and RAS/BRAF mutation
status (adjusted HR, 1.78 (95% CI 1.34–2.37); P < 0.001), as shown
in Supplementary Table 2.
Serum CA 19-9 level as a prognostic biomarker
There was a statistically signiﬁcant relationship between levels of
CA 19-9 (grouped in quartiles) and OS (log-rank test for trend,
P < 0.001). Figure 3b shows that an elevated serum CA 19-9 (≥35
kU/L) at baseline was associated with impaired outcome, with
median OS 17 months, compared to patients with CA 19-9 below
35 kU/L who had a median OS of 28 months (HR= 1.95 (95% CI
1.60–2.38); P < 0.001). Thirty-seven (20%) of the patients with
serum CA 19-9 level below 35 kU/L survived beyond 5 years,
compared to 5% of the patients with elevated CA 19-9, with no
difference in resection rates of metastases in the two groups
(10% and 8%, respectively). This association between elevated
CA 19-9 and impaired OS was found both in patients with low
and elevated serum level of CEA (Fig. 3c). Essentially, a similar
association was demonstrated in the groups of patients with
known RAS/BRAF mutation status or RAS/BRAF mutation and
plasma CRP level (not shown). There was a trend that the
prognostic value of elevated CA 19-9 was more pronounced in
patients with colon cancer compared to rectal cancer, but no
statistically signiﬁcant interaction between CA 19-9 and site on
OS was detected (not shown).
The baseline serum level of CA 19-9 or CEA did not inﬂuence
the initial chemotherapy response, measured as rates of overall
response, disease control, direct progression or secondary
resection of metastases, neither in the total patient population
nor in subgroups deﬁned by RAS or BRAF mutations (Supplemen-
tary Tables 3 and 4).
Paired serum samples obtained before the start of treatment
and after four cycles of chemotherapy (approximately 8 weeks of
treatment) were available from 384 and 260 patients with
elevated baseline levels of CEA and CA 19-9, respectively. There
was an association between treatment response and a drop in
serum levels for both markers (Supplementary Table 5). However,
the change, absolute or relative, in serum levels of CEA and CA 19-
9 did not predict prognosis better than the baseline level before
the start of treatment (not shown).
For 51 patients (9%), CA 19-9 was not detectable in the serum
samples as judged by the lower reference value. However, in this
subgroup 33 of the patients (6% of the analysed population) had
no analytic signal or very low values classiﬁed as analytic noise,
whereas 18 patients had CA 19-9 values between 3 and 5 kU/L,
below the lower analytical reference value. These data suggest
that at least 2/3 of the patients with no detectable CA 19-9 had Le
(a-b-) genotype in the Lewis blood group system, consistent with
the reported frequency of 5% to 10% of individuals lacking
expression of Lewis antigens in Caucasian populations.18,28 The
subgroup of patients for whom CA 19-9 could not be detected
showed clinical features that were essentially similar to the total
population (Table 1) and there was no statistically signiﬁcant
difference between the subcategories and clinical outcome
(Supplementary Figure 1A). Sensitivity analyses including these
patients with CA 19-9 assigned the value 0 did not signiﬁcantly
alter the results of the study (not shown).
Serum levels of CA 19-9 and tumour BRAF mutation status
The data showed that the prognostic information from elevated
levels of CA 19-9 differed depending on the RAS and BRAF
mutation status of the tumour, with a statistically signiﬁcant
interaction in adjusted analyses (P= 0.003). In contrast, there was
no statistically signiﬁcant interaction between serum CEA level
and RAS/BRAF mutation status (P= 0.27).
Elevated levels of CA 19-9 were associated with a particularly
impaired OS in BRAF-mutant cancers. The patients with BRAF-
mutant tumours had an estimated median OS of 17 and 9 months
in unadjusted analyses stratiﬁed on low and elevated serum levels
of CA 19-9, respectively, and the two groups differed signiﬁcantly
in the tail of the Kaplan–Meier curves (Fig. 3d). In an adjusted
proportional hazards model including WHO performance status
and levels of ALP, CEA and CRP, an elevated level of serum CA 19-9
was associated with a signiﬁcant relative reduction in survival
(adjusted HR= 4.35 (95% CI 2.89–8.28) in patients with tumours
harbouring BRAF mutation (Table 2).
In the NORDIC-VII patient cohort, we previously reported that an
elevated level of IL-6 was associated with an impaired prognosis,
especially in patients with BRAF-mutant tumours.22 To examine
the relationship between CA 19-9 and IL-6, we included
information about IL-6 levels (cut-off value 5.6 ng/L) in the analysis
of how CA 19-9 predicts OS. Table 3, showing results from patients
with BRAF-mutant tumours, demonstrates that at high levels of IL-
6 with poor survival there was still a further impaired outcome
associated with high CA 19-9. This suggests that IL-6 and CA 19-9,
at least partly, reﬂect independent mechanisms associated with
inferior prognosis.
Table 2. Association between prognostic factors and overall survival
in 388 patients with detectable serum levels of CA 19-9a
Variables HR 95% CI P value
RAS/BRAF mutation status
RAS/BRAF wild-type 0.003b
CA 19-9 <35 kU/L 1
CA 19-9 ≥35 kU/L 1.35 0.96–1.91
RAS mutation
CA 19-9 <35 kU/L 1
CA 19-9 ≥35 kU/L 1.43 1.00–2.05
BRAF mutation
CA 19-9 <35 kU/L 1
CA 19-9 ≥35 kU/L 4.35 2.89–8.28
CEA level
<5 µg/L 1 0.036
≥5 µg/L 1.41 1.02–1.94
WHO performance status
0 1 0.004
1 1.37 1.07–1.76
2 2.56 1.31–3.89
Alkaline phosphatase level
Normal 1 0.003
>UNL 1.44 1.13–1.82
CRP level
Per categoryc 1.17 1.05–1.31 0.006
CI conﬁdence interval, CEA carcinoembryonic antigen, CA carbohydrate
antigen, CRP C-reactive protein, HR hazard ratio, OS overall survival, UNL
upper normal limit, WHO World Health Organization a Adjusted model
including the interaction between tumour RAS/BRAF mutation status and
CA 19-9. b Interaction P. c CRP categories: from 0 to 10mg/L, from 10 to 30
mg/L, from 30 to 60mg/L, from 60mg/L and higher.
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DISCUSSION
The present results add new information about the two serum
biomarkers CEA and CA 19-9, both of which are routinely used
in the management of gastrointestinal cancers. The data
provide evidence that elevated serum levels of CEA and CA
19-9, measured before the start of ﬁrst-line chemotherapy, are
independent, negative prognostic factors in patients with
mCRC.
The relationship between elevated baseline CEA and impaired
prognosis is in line with previous studies on patients with
metastatic disease.13,29,30 The present results indicate that CEA is
an independent prognostic biomarker in mCRC in adjusted
models including RAS/BRAF mutation status. In addition, we want
to bring attention to the favourable OS and the substantial
proportion of long-term survivors in the patients with a baseline
serum level of CEA below 5 µg/L.
The results showed that CA 19-9 can also give valuable
prognostic information in mCRC. Elevated CA 19-9 serum levels
were associated with impaired prognosis, consistent with reported
data on mCRC in patients with unresectable liver metastases.15,31
This was independent of the CEA level at baseline and was
conﬁrmed in adjusted analyses. It has been suggested that CA 19-
9 could be used to monitor the disease development in mCRC
patients who have no elevation of CEA.32 Like CEA, low levels of
CA 19-9 were associated with a quite high percentage of survivors
beyond 5 years.
A major ﬁnding was that the present study suggests that
elevated serum CA 19-9 can have a particular role in patients with
BRAF-mutant mCRC. Thus, the median CA 19-9 level was
numerically high in patients with BRAF-mutant tumours and
50% of those with an isolated elevated CA 19-9 (low CEA) had
BRAF-mutant tumours. More importantly, an elevated CA 19-9
level was associated with short OS within the BRAF-mutant
subgroup of patients. It is known that the presence of BRAF
mutation in mCRC predicts impaired outcome;2,4,6,33 however,
these cancers are heterogeneous.9,19,20 Although the underlying
mechanisms are not clariﬁed, the present ﬁndings suggest that CA
19-9 may help identify one subgroup of BRAF-mutant mCRC
patients with particularly poor prognosis. On the other hand, the
measured serum CA 19-9 did not predict initial response to
chemotherapy, and an elevated level was not associated with
resistance to chemotherapy, neither in patients with BRAF-mutant
nor non-BRAF-mutant tumours.
We recently reported an association between high levels of
inﬂammation biomarkers and poor prognosis in mCRC, and this
was particularly prominent in the subset of patients with BRAF-
mutant tumours.22 Thus, in mCRC patients with BRAF-mutant
tumour, unlike RAS-mutant or RAS/BRAF double wild-type
tumours, high serum IL-6 predicted markedly impaired survival.
An obvious question, therefore, was whether high CA 19-9
identiﬁes the same patients as elevated IL-6. The present data
indicate that this is not the case and that IL-6 and CA 19-9 are
independent biomarkers. Thus, patients with combined high CA
19-9 and high IL-6 had extremely short survival. Together, the
results strengthen the indications that BRAF-mutant mCRC is
heterogeneous and suggest that IL-6 and CA 19-9 are biomarkers
of at least partly different mechanisms that underlie aggressive
disease.
One of the ﬁndings in a recent large investigation analysing the
outcomes of patients with mCRC with BRAF mutations was that
the most marked divergence between the BRAF-mutant and wild-
type cancers occurred following progression on or after beneﬁt
from ﬁrst-line chemotherapy.9 Our results with serum CA 19-9,
CEA, IL-6 and CRP strongly suggest that the prognostic prediction
provided by these biomarkers also largely concerns advanced
stages of mCRC. Thus, a marked difference in OS was noted
between cases with high and low levels of the inﬂammatory
markers despite relatively small differences in PFS.22 Furthermore,
in the present study, focusing on OS, we observed that for both
CEA and CA 19-9 the difference between the survival curves
representing high and low levels of these markers was also
reﬂected in long-term survival. This was so in the whole cohort
and was quite dramatic when comparing low and high CA 19-9 in
the subset of BRAF-mutant patients. Collectively, these data
suggest that in addition to BRAF mutations, several other
mechanisms, including inﬂammatory reactions as well as pro-
cesses reﬂected in elevated levels of carbohydrate/glycoprotein
markers, impair the outcome of mCRC by inﬂuencing the
advanced course of the disease. These mechanisms are likely
inherent in the phenotype of the particular cancer and some of
them can potentiate the effect of mutated BRAF. Hopefully, better
insights into these mechanisms may provide clues for developing
novel therapeutic strategies for advanced mCRC.
We are aware of some limitations for CA 19-9 as a biomarker,
since several benign diseases may also give rise to elevated levels,
and CA 19-9 is not expressed in subjects with Le (a-b-) genotype in
the Lewis blood group system. In this study, the Lewis blood-type
status of the patient cohort was unknown. Nine percent of the
patients in our cohort had no detectable CA 19-9 as judged by the
lower reference value, and in a clinical routine setting, these
patients will be reckoned as having a very low serum level of CA
19-9 below a detection limit, but it will not be possible to
distinguish between patients with very low CA 19-9 levels from
those who do not express CA 19-9 due to their Lewis blood type.
This subgroup of patients had clinical characteristics and outcome
that did not differ signiﬁcantly from the total population with
detectable levels of CA 19-9, suggesting that it included patients
across the total population and not speciﬁcally those with a low
CA 19-9 level.
Serum CA 19-9, alone or in combination with markers of
systemic inﬂammation, can be useful in the management of
patients with BRAF-mutant, primary unresectable mCRC. We
believe that the ﬁndings are of general relevance, although the
underlying chemotherapy regimen in the present study is not
commonly used outside the Nordic countries. Elevated serum CA
19-9 level may help to identify patients with a highly aggressive
disease, like those who should be considered for intensive ﬁrst-
line therapy, such as the triple combination FOLFOXIRI.4,34 In
conclusion, integrated prognostic data, including the CEA and CA
19-9 biomarkers, may give more accurate information about the
disease and can be useful in shared decision-making, enabling
patient and clinician to establish an optimal treatment plan.
Table 3. Outcome in 42 patients with BRAF-mutant tumours: OS in subgroups deﬁned by baseline level of CA 19-9 and IL-6
Variables n Events Median OS (95% CI) HR (95% CI)
CA 19-9 <35 kU/L IL-6 <5.6 ng/L 10 9 26.0 (15.2–36.8) 1
CA 19-9 ≥35 kU/L IL-6 <5.6 ng/L 7 7 11.8 (9.4–14.1) 4.3 (1.3–14.0)
CA 19-9 <35 kU/L IL-6 ≥5.6 ng/L 6 6 6.3 (5.2–7.4) 4.8 (1.5–14.9)
CA 19-9 ≥35 kU/L IL-6 ≥5.6 ng/L 19 19 8.1 (2.3–13.9) 9.0 (3.0–26.9)
IL-6 interleukin-6, CA carbohydrate antigen, CI conﬁdence interval, HR hazard ratio, OS overall survival
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